Vaxart, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a dichotomy between impressive top-line growth and systemic structural risks. While the shift to net profitability is a positive signal for a clinical-stage biotech, the quality of those earnings is tied heavily to government discretion and the successful delivery of Phase 2b data. The transition to a profitable state is largely a result of the specific accounting treatment of government grants and collaboration fees rather than commercial product sales. Investors must weigh the potential of Vaxart's oral vaccine platform against the reality of its OTC status and leveraged balance sheet. The upcoming 12-month follow-up data from the sentinel cohort in the first half of 2026 will likely serve as the primary catalyst, determining whether the Sanofi partnership converts into a $50 million payment or if the company faces a liquidity crunch as it nears the end of its projected 2027 runway.